[1]赵凯凯,司友娇,黄九宁,等.肝癌患者TACE术后对比剂肾病的危险因素[J].介入放射学杂志,2019,28(10):942-946.
 ZHAO Kaikai,SI Youjiao,HUANG Jiuning,et al.The risk factors for contrast- induced nephropathy in patients with HCC after TACE[J].journal interventional radiology,2019,28(10):942-946.
点击复制

肝癌患者TACE术后对比剂肾病的危险因素()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
28
期数:
2019年10期
页码:
942-946
栏目:
血管介入
出版日期:
2019-10-25

文章信息/Info

Title:
The risk factors for contrast- induced nephropathy in patients with HCC after TACE
作者:
赵凯凯 司友娇 黄九宁 张淑萍   王学雷   曲凡勇
Author(s):
ZHAO Kaikai SI Youjiao HUANG Jiuning ZHANG Shuping WANG Xuelei QU Fanyong.
Department of Radiation Oncology, Yantai Affiliated Hospital of Binzhou Medical College, Yantai, Shandong Province 264100, China
关键词:
【关键词】 肝癌 肝动脉化疗栓塞术 对比剂肾病
文献标志码:
A
摘要:
【摘要】 目的 分析肝癌患者行动脉栓塞化疗(TACE)术后对比剂肾病(CIN)的危险因素。方法 回顾性分析252例肝癌患者共行424次TACE治疗,根据是否发生CIN分为两组,对相关危险因素进行单因素及多因素分析。结果 共31例患者(7.3%)发生CIN。单因素分析表明,伴高血压、糖尿病、白细胞数低、低血红蛋白,高肌酐值、eGFR、TACE次数、腹水是术后 CIN 发生的危险因素(P<0.05)。多因素分析显示,高血压、白细胞数低、高肌酐值、低血红蛋白、多TACE次数可作为TACE术后 CIN 发生的独立危险因素。结论 CIN是接受TACE治疗的肝癌患者常见的并发症。高血压、贫血、白细胞数低、高肌酐值、多TACE次数为TACE术后CIN发生的独立危险因素。

参考文献/References:

[1] Nash K, Hafeez A, Hou S. Hospital- acquired renal insufficiency[J]. Am J Kidney Dis, 2002, 39: 930- 936.
[2] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53: 1020- 1022.
[3] Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines[J]. Eur Radiol, 2011, 21: 2527- 2541.
[4] Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group[J]. Ann Intern Med, 1999, 130: 461- 470.
[5] 周 兵, 程永德. 介入诊疗中提倡使用等渗性对比剂[J]. 介入放射学杂志, 2012, 21: 89- 91.
[6] 丁 力, 庄国红, 丁 飚. 静脉水化和口服水化预防心功能不全患者对比剂肾病临床应用[J]. 介入放射学杂志, 2016, 25: 15- 18.
[7] Sharma SK, Kini A. Effect of nonionic radiocontrast agents on the occurrence of contrast- induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials[J]. Catheter Cardiovasc Interv, 2005, 65: 386-393.
[8] Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac angiography in renally impaired patients(CARE) study: a randomized double-blind trial of contrast- induced nephropathy in patients with chronic kidney disease[J]. Circulation, 2007, 115: 3189- 3196.
[9] Hayakawa K, Tanikake M, Kirishima T, et al. The incidence of contrast- induced nephropathy(CIN) following transarterial chem- oembolisation(TACE) in patients with hepatocellular carcinoma (HCC)[J]. Eur Radiol, 2014, 24: 1105-1111.
[10] 徐 婧, 李春红, 王冰月, 等. 肝癌TACE治疗导致造影剂肾损害的相关危险因素分析[J]. 继续医学教育, 2017, 31: 100-103.
[11] Fox CS, Muntner P, Chen AY, et al. Short- term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry[J]. Circulation, 2012, 125: 497- 504.
[12] Park J, Chung HC, Lee JS, et al. Acute kidney injury after transarterial chemoembolization for hepatocellular carcinoma: a retrospective analysis[J]. Blood Purif, 2008, 26: 454- 459.
[13] Schrier RW, Wang W, Poole B, et al. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy[J]. J Clin Invest, 2004, 114: 5-14.
[14] Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast- induced nephropathy after percutaneous coronary interventions[J]. Kidney Int, 2005, 67: 706-713.
[15] Xu J, Zhang M, Ni Y, et al. Impact of low hemoglobin on the development of contrast- induced nephropathy: a retrospective cohort study[J]. Exp Ther Med, 2016, 12: 603- 610.
[16] 贾高鹏, 王悦喜. 对比剂肾病的预防治疗进展[J]. 心肺血管病杂志, 2018, 37: 79-82.
[17] Hsu CY, Huang YH, Su CW, et al. Transarterial chemoem bolization in patients with hepatocellular carcinoma and renal insufficiency[J]. J Clin Gastroenterol, 2010, 44: e171- e177. [18] 滕皋军 .对比剂肾病: 介入手术必须重视的并发症[J]. 介入放射学杂志, 2008, 17: 457- 458.
[19] 王玉萍, 沈世林, 苏东君, 等. 对比剂肾病研究进展[J]. 介入放射学杂志, 2017, 26: 572- 575.
[20] Min YW, Kim J, Kim S, et al. Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. Liver Int, 2013, 33: 197- 202.
[21] Massicotte A. Contrast medium-induced nephropathy: strategies for prevention[J]. Pharmacotherapy, 2008, 28: 1140-1150.
[22] Huo TI, Wu JC, Lee PC, et al. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study[J]. Liver Int, 2004, 24: 210-215.
[23] Cho HS, Seo JW, Kang Y, et al. Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization[J]. Clin Exp Nephrol, 2011, 15: 714-719.
[24] 苏津自, 薛 艳, 蔡文钦, 等. 高敏C反应蛋白水平与阿托伐他汀对急性冠状动脉综合征患者对比剂所致肾功能损害影响的关系[J]. 中华心血管病杂志, 2011, 39: 807- 811.
[25] Oda E, Kawai R, Aizawa Y. Lymphocyte count was significantly associated with hyper- LDL cholesterolemia independently of high-sensitivity C- reactive protein in apparently healthy Japanese[J]. Heart Vessels, 2012, 27: 377- 383.
[26] Kaya A, Kurt M, Tanboga IH. Neutrophil- to- lymphocyte ratio predicts contrast- induced nephropathy in patients undergoing primary percutaneous coronary intervention[J]. Angiology, 2014, 65: 59.
[27] 叶 飘, 谭 宁, 陈纪言, 等. 中性粒细胞/淋巴细胞比值与急性心肌梗死患者行急诊经皮冠状动脉介入治疗术后对比剂肾病发生的相关性[J]. 中国介入心脏病学杂志, 2014, 22: 84- 88.

相似文献/References:

[1]叶更新,曾文,杜德坤,等.肝动脉栓塞与经皮碘油标记酒精注射联合治疗晚期肝癌[J].介入放射学杂志,1996,(01):42.
[2]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
 .The volume of Lipiodol used in TACE: its current situation and research progress [J].journal interventional radiology,2012,(10):348.
[3]施长杲,吕维富,鲁 东,等.肝动脉化疗栓塞术后并发肝脓肿5例治疗分析[J].介入放射学杂志,2011,(04):273.
 SHI Chang-gao,LV Wei-fu,LU Dong,et al.The treatment of liver abscess occurred after transcatheter arterial chemoembolization report of five cases[J].journal interventional radiology,2011,(10):273.
[4]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗30例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
 ,,et al.TACE combined with radiofrequency ablation for massive primary hepatocellular carcinomas: a clinical therapeutic evaluation [J].journal interventional radiology,2012,(10):322.
[5]张   磊,陆骊工,李   勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
 ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(10):968.
[6]敖 劲,张跃伟,徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J].介入放射学杂志,2011,(12):1010.
 AO Jin,ZHANG Yue-wei,XU Ke..Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research[J].journal interventional radiology,2011,(10):1010.
[7]杜丹丹,吕维富. 肝癌射频消融后的影像学评价[J].介入放射学杂志,2012,(01):75.
 DU Dan dan,Lv Wei fu..Imaging evaluation of liver cancer after radiofrequency ablation therapy[J].journal interventional radiology,2012,(10):75.
[8]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
 ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(10):78.
[9]何海涛,刘 圣,刘建秦,等. 肝癌TACE术并发脑碘油栓塞二例并文献复习[J].介入放射学杂志,2012,(08):682.
 HE Hai- tao,LIU sheng,LIU Jian- qing,et al. Cerebral Lipiodol embolism occurred after transcatheter arterial chemoembolization for hepatocellular carcinoma: report of two cases with literature review[J].journal interventional radiology,2012,(10):682.
[10]刘纪营,马 南,管 生,等. 预防性应用抗生素的不同方法对介入治疗并发肝脓肿的影响[J].介入放射学杂志,2013,(06):474.
 LIU Ji? ying,MA Nan,GUAN Sheng,et al. The influence of different using methods of antibiotic prophylaxis on the occurrence of liver abscess after transcatheter hepatic arterial chemoembolization[J].journal interventional radiology,2013,(10):474.
[11]纪建红,郑群丽,陈思倩,等.TACE联合射频消融术治疗巨块型肝癌的护理[J].介入放射学杂志,2013,(12):1052.
 JI Jian? hong,ZHENG Qun? li,CHEN Si? qian,et al.Nursing care for patients with massive hepatocellular carcinoma receiving combination therapy of TACE and radiofrequency ablation[J].journal interventional radiology,2013,(10):1052.
[12]臧 爽,徐 阳,梁松年.原发性肝癌患者经肝动脉化疗栓塞术后住院天数影响因素的多元线性回归分析[J].介入放射学杂志,2015,(01):80.
 ZANG Shuang,XU Yang,LIANG Song nian..Multiple linear regression analysis of factors related to the hospitalization days in HCC patients after transcatheter hepatic arterial chemoembolization[J].journal interventional radiology,2015,(10):80.
[13]任文君,王泽阳,黄 欣,等.肝动脉化疗栓塞术联合125I放射性粒子植入术与单独肝动脉化疗栓塞术治疗肝癌的meta分析[J].介入放射学杂志,2019,28(02):132.
 REN Wenjun,WANG Zeyang,HUANG Xin,et al.TACE combined with 125I seed implantation vs simple TACE for the treatment of liver cancer: a meta analysis[J].journal interventional radiology,2019,28(10):132.
[14]江海林,孟小茜,廖华强,等.不同体位经桡动脉途径行TACE术的透视时间对比[J].介入放射学杂志,2021,30(03):275.
 JIANG Hailin,MENG Xiaoxi,LIAO Huaqiang,et al.Comparison of fluoroscopic time between different body positions in performing TACE via radial approach[J].journal interventional radiology,2021,30(10):275.
[15]李虎子,段振东,赵 成,等.TACE联合冷冻消融治疗不可切除肝癌临床疗效的meta分析[J].介入放射学杂志,2021,30(08):804.
 LI Huzi,DUAN Zhendong,ZHAO Cheng,et al.TACE combined with cryoablation for inoperable liver cancers: a meta analysis of clinical efficacy[J].journal interventional radiology,2021,30(10):804.
[16]刘秀芳,张伟伟,吴海平,等.多学科协作干预模式在TACE治疗原发性肝癌患者中的应用效果 [J].介入放射学杂志,2021,30(10):1057.
 LIU Xiufang,ZHANG Weiwei,WU Haiping,et al.The application value of multi-disciplinary team intervention mode in HCC patients receiving TACE[J].journal interventional radiology,2021,30(10):1057.

备注/Memo

备注/Memo:
(收稿日期:2019-02-25)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2019-10-17